Fluidigm Corporation (now identified in the request as Standard BioTools Inc.) — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; the filing also reports fourth-quarter results. The registrant named in this filing is Fluidigm Corporation.
Business context and financial performance
Fluidigm develops and sells life-science research instruments, consumables, and services for genomic and protein analysis, including single-cell analysis and mass cytometry. Its customers include academic and clinical research laboratories, biopharma and biotech companies, and agricultural biotechnology businesses. Products were marketed for research use only.
| Metric | FY2016 | FY2015 |
|---|---|---|
| Total revenue | $104.4 million | $114.7 million |
| Product revenue | $89.0 million | $102.1 million |
| Service revenue | $15.2 million | $12.3 million |
| Operating loss | $73.2 million | $50.2 million |
| Net loss | $76.0 million | $53.3 million |
| Net loss per share, basic and diluted | $2.62 | $1.86 |
| Net cash used in operating activities | $39.1 million | $34.7 million |
- Revenue fell 9% year over year. Instrument revenue declined 20%, mainly from lower unit sales across instrument systems, particularly C1; consumables revenue fell 3%. Service revenue grew 23%, reflecting a larger installed base and related support offerings.
- Product margin declined to 54% from 58%; service margin was 68%, down from 71%. Higher acquisition-related amortization, lower instrument prices, and reduced consumables capacity utilization weighed on product margin.
- Research and development expense was $38.4 million, down 2%; selling, general and administrative expense increased 12% to $93.2 million. The company reported an operating margin of approximately negative 70%.
- At year-end, cash and cash equivalents were $35.0 million and short- and long-term investments totaled $24.4 million. Working capital, excluding deferred revenue, was $76.3 million, versus $123.4 million a year earlier. Total assets were $306.4 million and stockholders’ equity was $53.2 million.
- Convertible notes had $201.3 million principal outstanding and a net balance-sheet carrying value of $195.0 million. The notes bear 2.75% interest and mature in 2034, subject to conversion, redemption, and repurchase provisions.
Material changes and unusual items
- Revenue declined for a second consecutive year: 1% in 2015 and 9% in 2016. Europe was a major source of the 2016 decrease, particularly lower instrument sales; Asia-Pacific revenue increased, driven in part by China.
- Net loss widened to $76.0 million. SG&A rose while revenue fell; operating cash use increased to $39.1 million from $34.7 million.
- The filing reports $11.2 million of annual amortization of DVS-acquired developed technology in both 2016 and 2015. Goodwill of $104.1 million was not impaired in the annual fourth-quarter assessments.
- Fourth-quarter 2016 revenue was $25.1 million and net loss was $17.7 million, compared with fourth-quarter 2015 revenue of $30.7 million and net loss of $12.9 million.
- Foreign-currency losses were $1.5 million in 2016. No grant revenue was recorded in 2016 or 2015; license revenue was $0.2 million in 2016.
Outlook, commentary, and risks
- Management said existing cash, cash equivalents, and investments were expected to cover working-capital and capital-expenditure needs for at least 18 months, while noting that additional financing could be needed depending on operating performance, spending, and cost-savings results.
- Beginning in the first quarter of 2017, the company implemented workforce reductions and facility optimization. It expected these initiatives to reduce 2017 operating expenses by approximately $8 million before severance costs. No specific revenue or earnings guidance is provided in the filing.
- Management expected research and development and SG&A expenses to decline in 2017 as the initiatives took effect, while warning that reduced investment could impair product development, marketing, or sales.
- The company was developing an Imaging Mass Cytometer platform for spatial analysis of proteins in tissue; it reported an initial prototype in 2016 and early-access commercial availability. Timing and commercial adoption remain uncertain.
- Key risks include sustained losses and cash burn, falling instrument demand, intense competition, long sales cycles, dependence on sole- or limited-source suppliers and concentrated manufacturing sites, product quality and yield issues, foreign exchange exposure, and potential impairment of goodwill or intangibles.
- Thermo Fisher Scientific added Fluidigm as a defendant in litigation alleging, among other matters, misappropriation of proprietary information and employment-related claims, and seeking damages and injunctive relief. The case was in its early stages; the company said it could not estimate the outcome or potential loss range. The legal contingency accrual was not material at year-end.
- The notes are structurally junior to subsidiary liabilities and effectively junior to secured debt to the extent of collateral value. Their indenture provides limited financial protections; scheduled holder repurchase dates include February 2021, 2024, and 2029.
- PricewaterhouseCoopers gave an unqualified opinion on the financial statements and concluded internal control over financial reporting was effective as of December 31, 2016.
Investor verification priorities
- Confirm subsequent revenue, instrument placements, consumables trends, and whether the 2017 cost reductions were achieved without undermining product development or customer support.
- Track cash burn and liquidity against management’s stated 18-month funding horizon, and assess potential financing needs and dilution risk.
- Review the convertible notes’ conversion, redemption, and put provisions alongside available liquidity and any new debt or security interests.
- Check the status and financial exposure of the Thermo Fisher litigation and any other material claims.
- Assess whether product-margin pressure, DVS-related amortization, and goodwill or intangible-asset impairment risks have changed.
- Monitor Imaging Mass Cytometer commercialization, regulatory developments affecting research-use-only products and laboratory-developed tests, and exposure to critical suppliers and manufacturing sites.